Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
Articolo
Data di Pubblicazione:
2021
Citazione:
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest) / Modlin, Irvin M; Kidd, Mark; Oberg, Kjell; Falconi, Massimo; Filosso, Pier Luigi; Frilling, Andrea; Malczewska, Anna; Salem, Ronald; Toumpanakis, Christos; Laskaratos, Faidon-Marios; Partelli, Stefano; Roffinella, Matteo; von Arx, Claudia; Kudla, Beata Kos; Bodei, Lisa; Drozdov, Ignat A; Kitz, Alexandra. - In: ANNALS OF SURGICAL ONCOLOGY. - ISSN 1534-4681. - 28:12(2021), pp. 7506-7517. [10.1245/s10434-021-10021-1]
Abstract:
Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Humans; Liquid Biopsy; Neoplasm Recurrence, Local; RNA, Messenger; Biomarkers, Tumor; Neuroendocrine Tumors
Elenco autori:
Modlin, Irvin M; Kidd, Mark; Oberg, Kjell; Falconi, Massimo; Filosso, Pier Luigi; Frilling, Andrea; Malczewska, Anna; Salem, Ronald; Toumpanakis, Christos; Laskaratos, Faidon-Marios; Partelli, Stefano; Roffinella, Matteo; von Arx, Claudia; Kudla, Beata Kos; Bodei, Lisa; Drozdov, Ignat A; Kitz, Alexandra
Link alla scheda completa:
Pubblicato in: